Equities

Bellring Brands Inc

Bellring Brands Inc

Actions
Consumer Staples Food Producers
  • Price (USD)57.42
  • Today's Change0.24 / 0.42%
  • Shares traded738.94k
  • 1 Year change+54.90%
  • Beta0.8491
Data delayed at least 15 minutes, as of May 04 2024 00:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BellRing Brands, Inc., formerly BellRing Distribution LLC, is a consumer product holding company. The Company is a provider of ready-to-drink (RTD) protein shakes, other RTD beverages, powders, nutrition bars and nutritional supplements. It operates through protein-based consumer goods. The Company’s primary brands are Premier Protein and Dymatize. Premier Protein’s product portfolio consists of RTD protein shakes, refreshing protein beverages, nutrition bars and protein powders. Dymatize brand’s portfolio includes an assortment of sports nutrition products, including primarily protein powders as well as nutritional supplements. Its products are distributed across a diverse network of channels, including club, food, drug and mass (FDM), e-commerce, specialty and convenience.

  • Revenue in USD (TTM)1.73bn
  • Net income in USD165.20m
  • Incorporated2021
  • Employees420.00
  • Location
    Bellring Brands Inc2503 S. Hanley RoadST. LOUIS 63144United StatesUSA
  • Phone+1 (314) 644-6400
  • Fax+1 (302) 636-5454
  • Websitehttps://bellring.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ionis Pharmaceuticals Inc787.65m-366.29m6.12bn927.00--15.67--7.77-2.56-2.565.502.680.28520.36212.77849,673.10-13.26-6.30-15.38-7.4498.8498.75-46.50-21.235.83--0.7671--34.105.60-35.80--11.83--
Immunitybio Inc622.00k-583.20m6.17bn628.00------9,914.25-1.13-1.130.0012-0.8750.0014--0.246990.45-134.71-112.76-377.77-316.07-----93,866.88-37,700.74---2.083.32--159.1767.62-40.00--18.48--
Exelixis Inc1.85bn205.05m6.38bn1.31k33.873.0427.703.450.64660.64665.847.210.6213.127.781,409,653.006.908.867.829.9195.7096.3011.1015.433.41--0.000.0013.6016.4713.98-21.343.98--
Elanco Animal Health Inc4.42bn-1.23bn6.69bn9.30k--1.07--1.51-2.50-2.508.9612.630.29591.185.39474,946.30-8.25-3.27-9.15-3.6556.2854.28-27.87-11.531.351.180.4813--0.1367.57-1,478.21--2.74--
Blueprint Medicines Corp282.21m-288.29m6.73bn645.00--21.60--23.86-4.82-4.824.594.960.24990.35316.18430,853.40-25.53-29.92-30.68-34.0696.97---102.15-116.653.61-23.370.4352--22.2241.149.06--4.85--
Cytokinetics, Inc.7.53m-526.24m6.83bn423.00------906.47-5.45-5.450.078-3.800.0082--10.5317,801.42-57.23-43.14-63.72-47.22-----6,988.63-540.47---16.522.66---92.04-24.89-35.30--9.76--
Revolution Medicines Inc11.58m-436.37m6.85bn378.00--3.62--591.87-3.77-3.770.102411.090.0081--3.9130,634.92-30.37-29.76-32.71-32.59-----3,768.28-606.93----0.00---67.27-10.50-75.46--38.82--
Jazz Pharmaceuticals PLC3.84bn330.79m6.93bn2.80k22.701.887.081.804.854.8555.4958.650.34360.64285.781,372,634.002.991.483.361.6289.5388.798.694.261.901.870.6070.004.7815.19285.14-1.49-20.04--
Vaxcyte Inc0.00-402.27m7.17bn254.00--5.07-----4.07-4.070.0013.010.00----0.00-33.33-34.22-36.11-37.21------------0.00-------80.00--107.28--
Intra-Cellular Therapies Inc464.37m-139.67m7.26bn610.00--11.21--15.64-1.46-1.464.846.140.62621.904.91761,262.30-18.84-38.27-21.89-42.7792.73---30.08-128.425.31--0.00--85.51--45.49---7.22--
Bellring Brands Inc1.73bn165.20m7.52bn420.0046.39--35.684.341.241.2412.99-2.192.395.899.624,129,762.0022.7818.8929.01--32.0832.449.5210.101.714.391.530.0021.5315.03101.0913.80-18.48--
Cerevel Therapeutics Holdings Inc0.00-432.84m7.74bn334.00--11.45-----2.66-2.660.003.710.00----0.00-38.29---41.29--------------0.3337-------23.14------
Legend Biotech Corp (ADR)285.14m-518.25m8.26bn1.80k--6.60--28.97-2.95-2.951.626.880.17949.685.70158,412.80-32.60-37.71-38.89-47.1949.42---181.75-286.516.83-24.230.208--143.7042.15-16.11--1.57--
Viking Therapeutics Inc0.00-93.72m8.49bn28.00--9.08-----0.9305-0.93050.008.470.00----0.00-16.76-21.91-17.52-23.04------------0.00-------24.73------
KBR Inc7.07bn-258.00m8.99bn34.00k--6.39--1.27-1.91-1.9152.6710.461.25--5.56207,970.60-4.450.4725-6.460.667813.8612.18-3.580.4122--1.170.5678340.005.977.20-240.21--36.3111.03
Data as of May 04 2024. Currency figures normalised to Bellring Brands Inc's reporting currency: US Dollar USD

Institutional shareholders

44.18%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Dec 202314.73m11.25%
The Vanguard Group, Inc.as of 31 Dec 202313.01m9.93%
Wasatch Advisors, Inc.as of 31 Mar 20245.98m4.57%
SSgA Funds Management, Inc.as of 31 Dec 20234.52m3.45%
Route One Investment Co. LPas of 31 Dec 20234.03m3.08%
T. Rowe Price Investment Management, Inc.as of 31 Dec 20233.70m2.83%
Franklin Advisers, Inc.as of 31 Dec 20233.63m2.77%
Geode Capital Management LLCas of 31 Dec 20232.87m2.19%
Dimensional Fund Advisors LPas of 31 Dec 20232.79m2.13%
AllianceBernstein LPas of 31 Dec 20232.59m1.98%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.